Allogene Corporate Overview November 2025 Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent that statements contained in this presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statem ...

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Chrisomalis has extensive experience as a private investor in the Biotech sector, leveraging his Applied Science background to create long-term value in Healthcare [2] - The Biotech Analysis Central group includes over 600 Biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist Healthcare investors [2]

Core Insights - Allogene Therapeutics reported a narrower loss of 19 cents per share for Q3 2025, compared to an expected loss of 23 cents and a loss of 32 cents per share in the same period last year [1][6] - The company's shares have decreased by 51% year-to-date, while the industry has seen an 11% growth [1] Financial Performance - Research and development (R&D) expenses were $31 million, a decrease of 30% from the previous year [3][6] - General and administrative (G&A) expenses fell by 16% year-over-year to approximately $14 million [3][6] - As of September 30, 2025, Allogene had $277 million in cash and cash equivalents, down from $303 million as of June 30, 2025 [3][6] 2025 Guidance - The company reiterated its guidance for 2025, expecting total operating expenses to be around $230 million, which includes nearly $45 million in non-cash stock-based compensation [4] - Cash burn for 2025 is anticipated to be around $150 million, with the current cash position expected to fund operations into the second half of 2027 [4][6] Pipeline Updates - Allogene is focused on the pivotal phase II ALPHA3 study for its lead drug cema-cel, targeting newly diagnosed large B-cell lymphoma patients [7] - The company has initiated the phase I RESOLUTION basket study for ALLO-329, exploring its potential in various autoimmune diseases, with data expected in the first half of 2026 [8] - Allogene is also developing ALLO-316, currently in the phase I TRAVERSE study for advanced renal cell carcinoma, and is seeking partnership opportunities for its development [9] Market Position - Allogene currently holds a Zacks Rank of 4 (Sell) [10]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company reported $277.1 million in cash, cash equivalents, and investments, with a cash runway extending into the second half of 2027 [17] - R&D expenses for Q3 2025 were $31.2 million, including $2.8 million of non-cash stock-based compensation, while G&A expenses were $13.7 million, including $5.9 million in non-cash stock-based compensation [17] - The net loss for Q3 was $41.4 million, or $0.19 per share, with an expected cash burn of approximately $150 million for 2025 [17][18] Business Line Data and Key Metrics Changes - The AlphaTru trial of cema-cel has been streamlined into a two-arm randomized study, with over 50 active sites across the U.S. and Canada, and expansion into Australia and South Korea expected early next year [8][9] - The Dagger technology has shown durable responses in nearly one-third of patients with metastatic kidney cancer, highlighting its potential in solid tumors [11][12] Market Data and Key Metrics Changes - The company is preparing for pivotal interim data from cema-cel in the AlphaTru trial and proof of concept from Allo329 in autoimmune disease, both expected to shape the next era of cell therapy [6][7] Company Strategy and Development Direction - The company aims to democratize access to cell therapies through Allogene XL Technology, which is designed to reduce costs and expand access to transformative treatments [5][6] - The focus remains on building scalable, reproducible therapies ready for patients, with significant milestones expected in the first half of 2026 [66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AlphaTru program and its potential to advance lymphoma treatment, with a focus on delivering meaningful clinical outcomes [11][15] - The company is optimistic about the upcoming milestones and believes they will validate the Allogene XL platform, shaping the company's trajectory [66] Other Important Information - The company is not waiting for the future of cell therapy but is actively creating it with a focus on data and a platform built for lasting impact [6][15] - The operational and scientific progress is supported by disciplined capital management, ensuring long-term value for shareholders [17][18] Q&A Session Summary Question: Can you see any data beyond MRD conversion for the futility analysis? - Management plans to focus on MRD conversion and not on primary endpoints for efficacy during the futility analysis [20][21] Question: What percentage of active sites are now able to start actively enrolling patients? - Nearly all of the over 50 active sites are open to enrollment, with only the most recently activated sites having minor setup tasks remaining [25][26] Question: What is the expected size and breadth of the data set for Allo329 next year? - Initial communication will involve a handful of patients showing biomarker and early clinical responses [29][30] Question: How many patients have consented for MRD testing in AlphaTru? - The pace of consenting has held steady, and the MRD positive rate is consistent with initial assumptions [33][34] Question: How are you controlling for variability in the MRD assay across different sites? - The MRD test is centrally conducted by Foresight Diagnostics, ensuring consistency in test performance [62][63]

Financial Performance - The company reported a net loss of $41.4 million and $152.1 million for the three and nine months ended September 30, 2025, respectively, with an accumulated deficit of $2.0 billion as of the same date [135]. - The net loss for the three months ended September 30, 2025, was $41.400 million, a reduction of 38% from a net loss of $66.293 million in 2024 [166]. - For the nine months ended September 30, 2025, the net loss was $152.1 million, a decrease of $45.6 million or 23.1% compared to a net loss of $197.7 million in 2024 [174]. Cash and Liquidity - The company has $277.1 million in cash and cash equivalents, expecting its cash runway to fund operations into the second half of 2027 [135]. - As of September 30, 2025, the company had cash and cash equivalents and investments totaling $277.1 million, consisting of bank deposits, money market funds, and available-for-sale securities [210]. - Cash used in operating activities for the nine months ended September 30, 2025, was $121.6 million, compared to $163.6 million in 2024, a decrease of $42.0 million or 25.7% [190]. - For the nine months ended September 30, 2025, cash provided by financing activities was $110.9 million, primarily from $105.3 million in net proceeds from the issuance of common stock [196]. - The primary use of cash is for operating expenses, including clinical manufacturing and research and development expenditures [197]. Research and Development - The company is focusing on three core programs: ALPHA3, RESOLUTION, and TRAVERSE clinical trials, while other product candidates are in pre-clinical studies [132]. - The ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) has over 50 activated trial sites in the U.S. and Canada, with additional sites in Australia and South Korea expected to open in early 2026 [120]. - ALLO-316 demonstrated a confirmed overall response rate (ORR) of 31% in patients with high CD70 expression, with 44% achieving at least a 30% reduction in tumor burden [128]. - The ALPHA3 trial's primary endpoint is event-free survival (EFS), targeting MRD-positive patients who are at high risk for relapse [121]. - The company anticipates proof-of-concept data for ALLO-329 by the first half of 2026, which will include both biomarker and clinical data [131]. - The company anticipates increased research and development expenses as clinical programs progress and additional product candidates are developed [157]. Expenses and Cost Management - Research and development expenses for the three months ended September 30, 2025, were $31.164 million, a decrease of 30% from $44.713 million in 2024 [166]. - General and administrative expenses decreased by 16% to $13.737 million in the three months ended September 30, 2025, compared to $16.333 million in 2024 [166]. - Total operating expenses for the three months ended September 30, 2025, were $44.901 million, down 37% from $71.774 million in 2024 [166]. - For the nine months ended September 30, 2025, total research and development expenses were $121.5 million, a decrease of $25.8 million or 17.5% compared to $147.3 million in 2024 [177]. - General and administrative expenses for the three months ended September 30, 2025, were $13.7 million, down from $16.3 million in 2024, a decrease of $2.6 million or 15.9% [169]. Strategic Collaborations and Agreements - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 for adult patients with advanced or metastatic renal cell carcinoma [127]. - The company has committed approximately $37.3 million in funding for the development of Foresight Diagnostics' MRD assay [152]. - The company has a minimum funding commitment for the overall development program under the Amended Notch Agreement [142]. - The company has committed up to $15.0 million for a strategic collaboration with MD Anderson, with upfront payments totaling $6.0 million made in 2020 and 2023 [202]. - The company has expanded its CD19 license territory to include the EU and the UK, with options to expand to China and Japan upon meeting certain conditions [133]. Market and Financial Risks - The company faces foreign exchange risk due to milestone payments in Euros under its collaboration agreement with Servier, with $23.5 million of deposits placed in escrow as of September 30, 2025 [211]. - The company expects to finance its cash needs through equity or debt financings and collaboration arrangements until substantial product revenue is generated [198]. - A 10% change in interest rates would not have a material effect on the fair market value of the company's cash equivalents and available-for-sale securities [210]. - The company has critical accounting policies related to accrued research and development expenditures, stock-based compensation, and leases, which significantly impact its financial statements [206]. Workforce and Operational Changes - The company initiated a workforce reduction of approximately 28% of its employees, incurring about $3.3 million in cash-based expenses related to severance payments and benefits [134].

Financial Performance - Allogene Therapeutics reported a net loss of $41.4 million for Q3 2025, or $0.19 per share, compared to a net loss of $66.3 million in Q3 2024[15] - Total operating expenses for Q3 2025 were $44.9 million, a decrease from $71.8 million in Q3 2024[19] - The company expects a decrease in cash, cash equivalents, and investments of approximately $150 million for 2025[11] - GAAP operating expenses for 2025 are projected to be approximately $230 million, including an estimated non-cash stock-based compensation expense of $45 million[11] Research and Development - Research and development expenses for Q3 2025 were $31.2 million, down from $44.7 million in Q3 2024[19] - The pivotal Phase 2 ALPHA3 trial with cema-cel is expected to conduct a futility analysis in the first half of 2026, focusing on minimal residual disease (MRD) conversion rates[6] - The Phase 1 RESOLUTION trial with ALLO-329 is exploring treatment regimens that may reduce or eliminate lymphodepletion, with proof-of-concept data anticipated in the first half of 2026[9] - Allogene's ALLO-316 trial in renal cell carcinoma has shown early signs of efficacy and tolerability, with plans for the next phase ongoing[10] Cash Position - The company ended Q3 2025 with $277.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027[11] - The company has over 50 active clinical sites in the U.S. and Canada for the ALPHA3 trial, with additional sites in Australia and South Korea expected to open in early 2026[5]

Core Insights - Allogene Therapeutics is advancing its allogeneic CAR T therapy portfolio aimed at improving access to cell therapy for cancer and autoimmune diseases, with a focus on earlier treatment and broader application [1][2] Financial Performance - For Q3 2025, the company reported a net loss of $41.4 million, or $0.19 per share, with total operating expenses of $44.9 million [14][19] - As of September 30, 2025, Allogene had $277.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027 [10][21] Clinical Trials and Developments - The pivotal Phase 2 ALPHA3 trial with cema-cel is exploring allogeneic CAR T therapy for earlier-line treatment of large B-cell lymphoma (LBCL), with over 50 clinical sites active in the U.S. and Canada, and additional sites expected to open in Australia and South Korea in early 2026 [3][6] - The next milestone for the ALPHA3 trial is a futility analysis expected in the first half of 2026, focusing on minimal residual disease (MRD) conversion rates [4][6] - The Phase 1 RESOLUTION trial with ALLO-329 is investigating a dual CD19/CD70 CAR for autoimmune diseases, with a focus on reducing or eliminating lymphodepletion to improve tolerability [5][7] - ALLO-316 is the only allogeneic CAR T therapy showing significant response rates in metastatic solid tumors, with the TRAVERSE trial in renal cell carcinoma demonstrating early signs of efficacy [8][6] Strategic Vision - The company aims to shift from personalized therapies to off-the-shelf treatments that can be more widely available, enhancing consistency, safety, and quality in cell therapy [2][12] - Allogene's approach leverages ex vivo manufacturing to improve the precision and control of cell products before administration to patients [2][12]

Core Insights - Allogene Therapeutics is presenting a Trial-in-Progress poster for the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) at the 2025 ASH Annual Meeting [1][2] Group 1: ALPHA3 Trial Overview - The ALPHA3 trial is a randomized study comparing cema-cel administered after standard FC lymphodepletion versus observation, the current standard of care [2] - The trial focuses on patients with large B-cell lymphoma (LBCL) who remain minimal residual disease (MRD) positive after first-line chemoimmunotherapy [2][3] - A futility analysis comparing MRD conversion between the two arms is expected in the first half of 2026 [3] Group 2: Cema-cel Product Details - Cema-cel is an investigational, next-generation anti-CD19 AlloCAR T product designed for immediate administration upon MRD detection [3][5] - The product received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in June 2022 for r/r LBCL [5] - Allogene holds oncology rights to cema-cel in the US, EU, and UK, with options for rights in China and Japan [5] Group 3: Market Context - Over 60,000 patients are expected to be treated for LBCL annually in the US, EU, and UK [6] - Approximately 30% of patients who initially respond to first-line treatment will relapse, necessitating subsequent treatment [6] - The ALPHA3 trial positions cema-cel as a potential "7th cycle" of frontline treatment for eligible patients with MRD [6] Group 4: Company Background - Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T products for cancer and autoimmune diseases [7] - The company aims to provide readily available cell therapy on-demand, more reliably, and at greater scale [7]

Core Points - Allogene Therapeutics will report its third quarter 2025 financial results and provide a business update on November 6, 2025, after market close [1] - A live audio webcast and conference call will follow the announcement at 2:00 p.m. PT/5:00 p.m. ET [1] - The listen-only webcast will be available on the company's website for approximately 30 days [2] Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to deliver "off-the-shelf" CAR T cell product candidates that are readily available on-demand, more reliably, and at greater scale to a larger patient population [4] - The management team has significant experience in cell therapy, which supports the company's development efforts [4] Conference Call Information - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]

Core Insights - ALLO Communications has launched the Smart Schools program in partnership with Calix, aimed at providing secure community Wi-Fi for Lincoln Public School students, promoting digital equity and extending learning opportunities beyond the classroom [1][3][5] Group 1: Program Details - Smart Schools is designed for students in grades 6-12, offering access to over 43,000 SmartTown Wi-Fi access points and includes a free first year of service for participating districts [3][5] - The program leverages Calix SmartTown technology, which utilizes Wi-Fi Alliance Passpoint architecture to ensure secure and authenticated online experiences in public spaces [3][6] Group 2: Community Impact - The initiative aims to bridge the "homework gap" by providing reliable online learning experiences across various community locations, including homes, libraries, and parks [3][6] - ALLO's approach is community-first, focusing on enhancing digital equity and strengthening local trust while expanding the program across Nebraska, Arizona, Colorado, and Missouri [7][8] Group 3: Leadership and Vision - ALLO CEO Brad Moline emphasized the importance of education and digital tools for students, stating that Smart Schools is a transformative movement ensuring students have secure internet access for their homework [8] - Calix CEO Michael Weening highlighted the collaborative vision that led to the creation of SmartTown, aiming to provide every child with safe and reliable internet access [8]